0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Bharat Biotech Dossier Under Review For Covaxin Emergency Use Listing Who
News Feed
course image
  • 20 Jul 2021
  • Admin
  • News Article

Bharat Biotech Dossier Under Review For Covaxin Emergency Use Listing WHO

World Health Organisation (WHO) had a meeting with those of Bharat Biotech and the Hyderabad-based vaccine maker's dossier for Emergency Use Listing (EUL) of Covaxin is under review by the technical experts for consideration, Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia said on Monday.Speaking to ANI, Dr Singh also informed that India has been offered 7.5 million doses of Moderna vaccine through WHO's COVID-19 Vaccines Global Access (COVAX) program.The WHO Regional Director said, "Pfizer, AstraZeneca, Moderna, Johnson and Johnson, Sinovac and Sinopharm have been granted EUL by the WHO. For COVXIN, an expression of interest for EUL has been made to WHO by Bharat Biotech. WHO has already conducted a pre-submission meeting with the company following which a dossier has been submitted by Bharat Biotech to WHO in early July. The dossier is currently under review by the technical experts for consideration of EUL." Cautioning about the possibility of the Delta variant of coronavirus becoming the most dominant COVID strain, Dr Singh said, "Delta variant has spread to over 100 countries, the way its spreading is likely to soon become the most dominant COVID strain globally.""Among all variants of concern, Delta spreads most rapidly. The rapid spread means more cases, leading to more pressure on health systems and more deaths," she said.The WHO South-East Asia director noted that globally, COVID cases and fatalities were again on the rise."The more we allow the virus to spread, the more it will evolve, resulting in more variants. We need to ensure that public health and social measures are implemented continuously. The interventions proven to be effective even against the delta variant," she said.Dr Singh also urged people to act 'urgently' to contain the spread of the COVID-19 virus and aggressively scale up vaccination especially of the vulnerable population for containment of the possible third wave."People are longing to go back to their normal lives which is understandable. However, we have to be reminded of the huge risk of letting our guards down. We witnessed that very recently and continue to do so globally even today. If we take the precautions, get vaccinated and leave no room for the virus to infect us, all of us together can contain the spread of the virus," she noted. She further informed that for the past ten consecutive weeks, COVID cases have been continuously increasing in some Eastern Mediterranean, European and Southeast Asian countries.Dr Singh also noted that cases are on a decline in India, Nepal, and Maldives. "However, the situation continues to be a concern,' she said."The pandemic isn't over anywhere. We must continue to strengthen our capacity. There is absolutely no room for complacency. We need to prevent another surge and scale up our response capacity along with our vaccination programmes," she added.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form